# Angio Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angio-lab

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.angiolab.co.kr
- Total disclosed funding: $6.8M
- Latest round: Series C (Sep 20, 2016)
- Investors on record: 4

## About

Based in Daejeon, South Korea, and founded in 1999, AngioLab, Inc. operates as a bio-venture company that developed therapies for angiogenesis-related diseases by inhibiting angiogenesis. In July 2019, Delta Investment and DT&Investment invested KRW 3 billion in Angio Lab, at KRW 18,000 per share, in a PIPE transaction. As of July 2023, the company is being led by its CEO, Kim Min Young. The firm operates as a biotechnological company with specialized technologies to develop and offer new therapies to treat various diseases such as cancer growth and metastasis, abdominal obesity, eye diseases, psoriasis, and arthritis based on angiogenesis inhibition-related candidates. The company also offers treatment for abdominal obesity, treatment of retinopathy such as macular degeneration, periodontal disease treatment, and anti-tank drugs.

## Funding rounds

- Series C, Sep 20, 2016, $6.8M — Shinhan Venture Investment, InterVest, Company K Partners, DT&Investment

## Investors

- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series C
- InterVest (https://capitalatlas.ai/funds/intervest) — Series C
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series C
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series C